Eckert & Ziegler Strahlen- und Medizintechnik AG (F:EUZ) — Market Cap & Net Worth
Market Cap & Net Worth: Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)
Eckert & Ziegler Strahlen- und Medizintechnik AG (F:EUZ) has a market capitalization of $878.60 Million (€751.51 Million) as of September 20, 2026. Listed on the F stock exchange, this Germany-based company holds position #9542 globally and #1176 in its home market, demonstrating a -1.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eckert & Ziegler Strahlen- und Medizintechnik AG's stock price €12.01 by its total outstanding shares 62573961 (62.57 Million). Also see EUZ asset base for a full breakdown of the balance sheet.
Eckert & Ziegler Strahlen- und Medizintechnik AG Market Cap History: 2015 to 2026
Eckert & Ziegler Strahlen- und Medizintechnik AG's market capitalization history from 2015 to 2026. Data shows growth from $299.15 Million to $878.60 Million (10.96% CAGR). Also see EUZ cash generation efficiency for how efficiently the company converts equity into cash flow.
Eckert & Ziegler Strahlen- und Medizintechnik AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eckert & Ziegler Strahlen- und Medizintechnik AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check EUZ stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.57x
Eckert & Ziegler Strahlen- und Medizintechnik AG's market cap is 3.57 times its annual revenue
Latest Price to Earnings (P/E) Ratio
22.86x
Eckert & Ziegler Strahlen- und Medizintechnik AG's market cap is 22.86 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $426.62 Million | $137.94 Million | $9.55 Million | 3.09x | 44.67x |
| 2017 | $570.69 Million | $138.63 Million | $14.70 Million | 4.12x | 38.82x |
| 2018 | $989.25 Million | $168.71 Million | $16.13 Million | 5.86x | 61.32x |
| 2019 | $3.08 Billion | $178.49 Million | $22.02 Million | 17.23x | 139.69x |
| 2020 | $3.16 Billion | $176.14 Million | $22.88 Million | 17.94x | 138.10x |
| 2021 | $6.70 Billion | $180.44 Million | $34.53 Million | 37.11x | 193.92x |
| 2022 | $3.32 Billion | $222.26 Million | $29.28 Million | 14.95x | 113.53x |
| 2023 | $2.99 Billion | $246.09 Million | $26.30 Million | 12.14x | 113.59x |
| 2024 | $3.21 Billion | $295.85 Million | $33.28 Million | 10.84x | 96.38x |
| 2025 | $1.11 Billion | $311.96 Million | $48.76 Million | 3.57x | 22.86x |
Competitor Companies of EUZ by Market Capitalization
Companies near Eckert & Ziegler Strahlen- und Medizintechnik AG in the global market cap rankings as of September 20, 2026. Review Eckert & Ziegler Strahlen- und Medizinte tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Eckert & Ziegler Strahlen- und Medizintechnik AG by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #124 globally with a market cap of $178.43 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #238 globally with a market cap of $105.53 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #124 | Abbott Laboratories | NYSE:ABT | $178.43 Billion | $102.61 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.13 |
| #238 | Stryker Corporation | NYSE:SYK | $105.53 Billion | $275.12 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Eckert & Ziegler Strahlen- und Medizintechnik AG Historical Marketcap From 2015 to 2026
Between 2015 and today, Eckert & Ziegler Strahlen- und Medizintechnik AG's market cap moved from $299.15 Million to $ 878.60 Million, with a yearly change of 10.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €878.60 Million | -21.19% |
| 2025 | €1.11 Billion | -65.24% |
| 2024 | €3.21 Billion | +7.36% |
| 2023 | €2.99 Billion | -10.12% |
| 2022 | €3.32 Billion | -50.36% |
| 2021 | €6.70 Billion | +111.87% |
| 2020 | €3.16 Billion | +2.75% |
| 2019 | €3.08 Billion | +210.92% |
| 2018 | €989.25 Million | +73.34% |
| 2017 | €570.69 Million | +33.77% |
| 2016 | €426.62 Million | +42.61% |
| 2015 | €299.15 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Eckert & Ziegler Strahlen- und Medizintechnik AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $878.60 Million USD |
| MoneyControl | $878.60 Million USD |
| MarketWatch | $878.60 Million USD |
| marketcap.company | $878.60 Million USD |
| Reuters | $878.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories… Read more